Clinical Tool

Evidence-Based Intervention Table

Evidence-Based Intervention Table

Quick Reference Tool | PsychHQ Source: Module 5, Evidence-Based Psychosocial Interventions | Last Updated: February 2026


The Core Principle

Medication addresses neurochemistry. Behavioral interventions build skills and restructure environments. Neither replaces the other. The AAP, NICE, CADDRA, and AADPA all recommend psychosocial interventions as integral to ADHD management — not optional supplements to pharmacotherapy.

The key distinction: ADHD involves both knowledge deficits (the child has never learned the skill) and performance deficits (the child knows what to do but cannot reliably execute it). Skills training targets knowledge deficits. Environmental restructuring targets performance deficits. Medication makes both more likely to succeed but teaches neither.


Intervention Evidence Hierarchy

Tier 1: Well-Established (Level 1 Evidence)

These three interventions have earned "Well-Established" classification from the APA Division 53 Task Force based on replicated RCT evidence. (Evans et al., 2014, J Clin Child Adolesc Psychol)

Reading the effect sizes below: SMD (standardized mean difference) and Hedges' g measure how much better the treatment group did compared to controls. Rough benchmarks: 0.2 = small, 0.5 = medium, 0.8 = large. For reference, stimulant medication for ADHD is about 0.8–1.0.

Intervention Target Age Mechanism Effect Sizes Key Evidence Best For
Behavioral Parent Training (BPT) 2–12 Modifies parenting behaviors: contingent reinforcement (rewarding target behaviors consistently), standardized discipline, antecedent restructuring (changing the environment before problems happen). The parent is the agent of change, not the child. Positive parenting: SMD 0.70; Parent stress: SMD 0.51; Observed parenting: SMD 0.41. Teacher-rated ADHD: negligible (setting-specific). PCIT: g = 0.90 for ADHD symptoms Fabiano et al. (2021); Doffer et al. (2023); Pelham et al. (2024) Preschool ADHD (AAP first-line, Grade A); school-age as combined treatment; ODD comorbidity; parent-child conflict
Behavioral Classroom Management (BCM) 5–18 Token economies, point systems, antecedent modifications, Daily Report Card (DRC). Implements contingencies in the school environment. Teacher-rated ADHD symptoms: SMD 0.66; Global impairment: SMD 0.72; DRC by blinded observation: d = 1.05 Fabiano et al. (2021); Yegencik et al. (2025); Iznardo et al. (2020) All school-age children with ADHD; behavioral problems in classroom; home-school communication
Organizational Skills Training (OST) Grades 3–8+ Directly teaches organization, time management, and planning (OTMP) skills. Addresses knowledge deficits — things the child has never learned how to do — that medication alone cannot fix. Parent-rated org skills: g = 0.83; Teacher-rated org skills: g = 0.54; GPA: g = 0.29. 60% no longer met OTMP impairment criteria post-treatment Abikoff et al. (2013); Bikic et al. (2017); Langberg et al. (2021) Disorganized students; homework completion problems; academic underperformance despite adequate cognitive ability

Named BPT Programs:

Program Target Age Key Features
PCIT (Parent-Child Interaction Therapy) 2–7 Live therapist coaching via one-way mirror; two phases (relationship building + limit setting)
Incredible Years 2–12 Group-based; video vignettes; international replication across cultures
Triple P (Positive Parenting Program) 0–16 Five-tiered population model; flexible intensity matching
New Forest Parenting Programme 3–8 Designed specifically for ADHD (not generic conduct problems); integrates ADHD psychoeducation

Named OST Programs:

Program Target Age Setting
Abikoff OST Grades 3–5 Clinic-based; 20 sessions; d = 2.77 on COSS (intervention-proximal)
HOPS (Homework, Organization, and Planning Skills) Middle school School-based; targets the transition when executive demands spike
CHP (Challenging Horizons Program) Middle/high school Year-long school integration; organization + study strategies + social behavior

Tier 2: Strong Evidence

Intervention Target Age Mechanism Effect Sizes Key Evidence Best For
CBT for Adult ADHD (Safren model) Adults 12-session "3+3" model: Organization/Planning → Distractibility Management → Adaptive Thinking. Externalizes working memory, implements structural systems, addresses negative self-narrative. Core symptoms: d = 1.19 (vs. TAU); significant improvement vs. active placebo on blinded CGI. Effects maintained at 6- and 12-month follow-up Safren et al. (2010) JAMA; Lopez et al. (2018) Cochrane Adults with residual symptoms despite medication; procrastination; executive dysfunction
STAND (Supporting Teens' Autonomy Daily) Adolescents Dyadic parent-teen format integrating motivational interviewing with organizational skills training. Active ingredients: OTP skills + improved parent-teen communication Significant improvements in ADHD symptoms, org skills, homework behavior, parenting stress. Effects maintained at 6-month follow-up Sibley et al. (2016, 2021, 2022) Adolescents; parent-teen conflict about school; medication non-adherence
Physical Exercise All ages Increases prefrontal dopamine and norepinephrine; improves inhibitory control acutely and chronically ADHD symptoms: g = −0.37; Social impairment: g = −0.54 (I² = 0%); Acute inhibitory control (adults): SMD = −0.65 Zheng et al. (2025); Yang et al. (2025); Lambez et al. (2022) Universal adjunct; all patients; especially those seeking non-pharmacological additions

Exercise prescription notes: Cognitively engaging activities requiring complex motor control (martial arts, dance, team sports) appear more effective than passive modalities (treadmill, standard yoga). Team sports add external structure, social engagement, and consistent scheduling. Exercise is complementary to medication and behavioral therapy, never a substitute.


Tier 3: Moderate Evidence / Specific Populations

Intervention Target Age Mechanism Effect Sizes Key Evidence Best For
Omega-3 Fatty Acids Children, adults Structural components of neural membranes; neuroinflammation modulation. Individuals with ADHD often show lower omega-3 levels. Significant only with >4 months duration: SMD = −0.35 (p = 0.007) Liu et al. (2023) J Clin Psychiatry; Barragán et al. (2017) Low-risk adjunct; families seeking nutritional approaches; possible methylphenidate dose-sparing effect (unconfirmed)
Few-Foods Diet (FFD) Children Intensive oligoantigenic elimination protocol; identifies individual food triggers ~60% of children responded with >40% symptom reduction; ES: 0.80 (parent), 0.51 (blinded observer) Pelsser et al. (2011) Lancet; Lange et al. (2024) Refractory cases; families preferring non-pharmacological approaches. Requires strict dietetic supervision. Not a first-line treatment
Mindfulness (adults) Adults Attention regulation training; meta-awareness g = −0.52 for ADHD symptoms; g = −0.69 for inattention Xue et al. (2019); 2025 BMJ umbrella review Adult ADHD; adjunct to medication and CBT. Limited evidence in children
Sleep Hygiene Interventions All ages Consistent bedtime routines, screen removal 30–60 min before sleep, reduced evening light exposure, graduated extinction Feasible and effective across neurodevelopmental disorders AAP (Wolraich et al., 2019) All patients — sleep problems affect 25–50% of children with ADHD and amplify every symptom domain
Melatonin Children, adolescents Addresses stimulant-induced sleep-onset latency Strong evidence base in pediatric ADHD populations Cortese et al. (2009) Stimulant-treated patients with sleep-onset insomnia

Tier 4: Weak, Experimental, or Not Recommended

Intervention What It Claims What the Blinded Evidence Shows Recommendation
Standard Neurofeedback EEG biofeedback claims to normalize the theta/beta ratio (the balance between "idling" and "alert" brainwaves); marketed as "drug-free cure" 2022 fMRI-NF RCT: no significant differences between active and sham on any endpoint. 2025 meta-analysis (Westwood et al., JAMA Psychiatry): overall probably-blinded SMD = 0.04 (NS); subgroup restricted to standard protocols only: SMD = 0.21. Unblinded parent reports inflate effects due to non-specific therapeutic factors — the child is getting 1:1 attention in a quiet structured setting, which helps regardless of what the EEG is doing. Not recommended. 30–40 sessions at high cost; effects indistinguishable from sham when properly blinded. Major opportunity cost risk.
CogMed / Computerized Cognitive Training Working memory training transfers to ADHD symptoms Near-transfer (improvement on tasks similar to the training): yes (verbal WM: SMD 0.38; visuospatial WM: SMD 0.49). Far-transfer (improvement on real-world tasks the training doesn't directly practice): SMD 0.12 (NS). No transfer to reading, arithmetic, or real-world functioning. Not recommended as ADHD treatment. Gets better at the game, but that improvement does not carry over to ADHD symptoms or functional outcomes.
Traditional Social Skills Training (SST) Teaches social skills in clinic settings Cochrane: SMD −0.26 for teacher-rated ADHD; high bias risk, low certainty. No durable gains that generalize to real life. Skills taught in a quiet clinic don't survive the schoolyard. Not recommended in traditional format. Context-embedded delivery (parent/teacher as "friendship coaches" in the child's natural settings) shows more promise.
EndeavorRx / Digital Therapeutics FDA-cleared video game improves ADHD Improvements on TOVA (near-transfer: game-like computerized attention task). Broader behavioral improvements likely attributable to placebo/expectancy. Currently Level 4 (Experimental). Not recommended as substitute for established treatments. Active area of development. See Digital Therapeutics Evidence Summary.
Herbal Supplements (St. John's Wort, Ginkgo, etc.) "Natural" ADHD treatment No consistent RCT evidence supporting efficacy for ADHD symptoms Not recommended. Potential drug interactions.

Critical Clinical Concepts

Setting-Specificity

Behavioral improvements in ADHD are generally confined to the environments where contingencies are actively managed. BPT improves behavior at home but shows negligible effects on teacher-rated classroom behavior (SMD −0.18 to 0.02). BCM improves classroom behavior but does not transfer home. This is not a flaw — it reflects the performance-deficit nature of ADHD. Gains require active environmental support.

The "Behavioral Therapy First" Paradigm

2024 sequencing evidence (Pelham et al., SMART trial): children who started with behavioral therapy before medication built stronger self-regulation skills than those who started with combined treatment. The mechanism makes intuitive sense: medication works so fast that parents never feel the urgency to master behavioral management techniques. When medication is later withdrawn, behavioral-first families cope better.

Applies to: Moderate ADHD severity where behavioral therapy has a realistic chance of initial gains. Does not apply to: Severe ADHD with safety concerns or dangerous impulsivity — do not delay pharmacotherapy.

Opportunity Costs

Neurofeedback (30–40 sessions, thousands of dollars, often not insured) and CogMed pursued instead of proven treatments delay effective care during critical developmental windows. Clinicians should explicitly communicate this calculus to families.

The Accommodation vs. Intervention Distinction

If a school plan lists only preferential seating, extended time, and fidgets, it is an accommodation plan, not an intervention plan. These accommodations have weak evidence bases as standalone ADHD supports. Advocate for the "Big Two" by name: Daily Report Card (DRC) and Organizational Skills Training (OST). See IEP/504 Letter Template for how to frame this in clinical documentation.


This quick reference tool is extracted from Module 5: Evidence-Based Psychosocial Interventions. For full evidence review, moderator analyses, treatment sequencing algorithms, and complete references, see the full clinical module.

For the full clinical curriculum, visit psychhq.com

Key References: Evans et al. (2014) J Clin Child Adolesc Psychol; Fabiano et al. (2021) Rev Educ Res; Abikoff et al. (2013) J Consult Clin Psychol; Safren et al. (2010) JAMA; Sibley et al. (2016) J Consult Clin Psychol; Pelham et al. (2016, 2024); Cortese et al. (2018) Lancet Psychiatry; Westwood et al. (2025) JAMA Psychiatry; Iznardo et al. (2020) J Atten Disord; Zheng et al. (2025) Medicine; Bikic et al. (2017) Clin Psychol Rev